Zhang X - Search Results

1

Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy.

Zhang X, Sjöblom T. Zhang X, et al. Pharmaceuticals (Basel). 2021 Jan 13;14(1):57. doi: 10.3390/ph14010057. Pharmaceuticals (Basel). 2021. PMID: 33450833 Free PMC article. Review.

2

The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy.

Hernlund E, Olofsson MH, Fayad W, Fryknäs M, Lesiak-Mieczkowska K, Zhang X, Brnjic S, Schmidt V, D'Arcy P, Sjöblom T, De Milito A, Larsson R, Linder S. Hernlund E, et al. Among authors: zhang x. Eur J Cancer. 2012 Feb;48(3):396-406. doi: 10.1016/j.ejca.2011.11.013. Epub 2011 Dec 7. Eur J Cancer. 2012. PMID: 22154651

3

Iron Chelator VLX600 Inhibits Mitochondrial Respiration and Promotes Sensitization of Neuroblastoma Cells in Nutrition-Restricted Conditions.

Jakobsson AW, Kundu S, Guo J, Chowdhury A, Zhao M, Lindell E, Bergsten P, Swartling FJ, Sjöblom T, Zhang X. Jakobsson AW, et al. Among authors: zhang x. Cancers (Basel). 2022 Jun 30;14(13):3225. doi: 10.3390/cancers14133225. Cancers (Basel). 2022. PMID: 35805002 Free PMC article.

4

Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity.

Zhang X, Akcan E, Correia M, Rameika N, Kundu S, Stoimenov I, Rendo V, Eriksson AU, Haraldsson M, Globisch D, Sjöblom T. Zhang X, et al. Biochem Pharmacol. 2022 Sep;203:115184. doi: 10.1016/j.bcp.2022.115184. Epub 2022 Jul 22. Biochem Pharmacol. 2022. PMID: 35872325 Free article.

5

Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells.

Lu X, Zhong L, Lindell E, Veanes M, Guo J, Zhao M, Salehi M, Swartling FJ, Chen X, Sjöblom T, Zhang X. Lu X, et al. Among authors: zhang x. Cell Death Dis. 2023 Oct 13;14(10):676. doi: 10.1038/s41419-023-06204-1. Cell Death Dis. 2023. PMID: 37833290 Free PMC article.

6

Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib.

Zhang X, Rameika N, Zhong L, Rendo V, Veanes M, Kundu S, Nuciforo S, Dupuis J, Al Azhar M, Tsiara I, Seeburger P, Al Nassralla S, Ljungström V, Svensson R, Stoimenov I, Artursson P, Heim MH, Globisch D, Sjöblom T. Zhang X, et al. EBioMedicine. 2024 Nov;109:105368. doi: 10.1016/j.ebiom.2024.105368. Epub 2024 Oct 4. EBioMedicine. 2024. PMID: 39368455 Free PMC article.

7

Eradicating Quiescent Tumor Cells by Targeting Mitochondrial Bioenergetics.

Zhang X, De Milito A, Demiroglu-Zergeroglu A, Gullbo J, D'Arcy P, Linder S. Zhang X, et al. Trends Cancer. 2016 Nov;2(11):657-663. doi: 10.1016/j.trecan.2016.10.009. Epub 2016 Nov 11. Trends Cancer. 2016. PMID: 28741504 Review.

8

Drug Development Targeting the Ubiquitin-Proteasome System (UPS) for the Treatment of Human Cancers.

Zhang X, Linder S, Bazzaro M. Zhang X, et al. Cancers (Basel). 2020 Apr 7;12(4):902. doi: 10.3390/cancers12040902. Cancers (Basel). 2020. PMID: 32272746 Free PMC article. Review.

9

Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries.

Zhang X, Shetty M, Clemente V, Linder S, Bazzaro M. Zhang X, et al. Int J Mol Sci. 2021 Apr 29;22(9):4750. doi: 10.3390/ijms22094750. Int J Mol Sci. 2021. PMID: 33947138 Free PMC article.

10

Quiescent Cancer Cells-A Potential Therapeutic Target to Overcome Tumor Resistance and Relapse.

Lindell E, Zhong L, Zhang X. Lindell E, et al. Among authors: zhang x. Int J Mol Sci. 2023 Feb 13;24(4):3762. doi: 10.3390/ijms24043762. Int J Mol Sci. 2023. PMID: 36835173 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

181,400 results

Search Page

Filters